Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ABCL
ABCELLERA BIOLOGICS INC.
NASDAQ
$11.35
▼ DOWN 8.47% (-1.05)

KEY STATISTICS

Market Cap$3.47 B
52w High$12.58
52w Low$2.75
Dividend Yield—
Frequency—
P/E-21.02
Volume5.84M
Shares Out.305.38M

COMPANY

LEADERSHIP

Carl Hansen
CHIEF EXECUTIVE
Carl Hansen

COMPENSATION 2026

Salary$550,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$23,244
Total$6,293,085

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 11, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
562

PRICE TARGET

Target High$30.00
Target Low$7.00
Target Median$9.00
Target Consensus$15.33

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$5.32M
NOV
5
THU

PRICE

$11.35 ▼ DOWN 8.47% (−$1.05)
$11.20$11.60$12.00$12.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM11.35

About AbCellera Biologics Inc.

https://www.abcellera.com ↗

AbCellera Biologics Inc., founded in 2012 in Vancouver, uses AI-driven platforms to discover antibodies, with 156 programs and collaborations including Eli Lilly.

INDUSTRY

Biotechnology

A PRODUCT ABCELLERA BIOLOGICS INC. IS KNOWN FOR

ABCL635
ABCL635

ABCL635 is an investigational, potentially first-in-class non-hormonal antibody for menopause-related hot flashes, marking AbCellera's shift to developing its own internal pipeline of antibody medicines.

COMPETITORS

COMPETITOR
ADPT COMPARE
OABI COMPARE
RXRX COMPARE
SDGR COMPARE
TWST COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License$138K $36.17M ▲— —
Research Fees$8.82M $7.68M ▼$8.12M ▲$3.9M ▼
Licensing and Royalty Revenue— — $191K $149K ▼

Revenue by Geography

MapREGIONFY2022FY2023FY2024FY2025
CANADA$484.2M $36M ▼$26.2M ▼$64M ▲
UNITED STATES$1.2M $2M ▲$2.7M ▲$11.1M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
26
LISTED HERE
12
RANKED BY POSITION SIZE
IBB
0.20% · 1.8M
CPAI
3.23% · 1.1M
SPDW
0.02% · 572.1K
ONEQ
0.02% · 135.5K
SILX
3.81% · 92.4K
AVUS
0.01% · 64.8K
BBC
1.42% · 59.9K
PDN
0.11% · 33.8K
BIB
0.12% · 10.9K
ACSG
0.21% · 8.8K
NIFE
1.39% · 5.0K
AP
APXH
0.25% · 35

INSTITUTIONAL OWNERSHIP

SHARES OWNED
36.65%
HOLDERS
204
TOP 12 OF 204 · RANKED BY POSITION SIZE
Baker Bros. Advisors LP
30.3M sh · $105.66M
Capital World Investors
13.4M sh · $45.69M
Two Sigma Investments, LP
10.6M sh · $36.86M
Baillie Gifford & Co
10.4M sh · $52.43M
Td Waterhouse Canada Inc.
9.6M sh · $33.57M
Ubs Asset Management Americas Inc
7.9M sh · $26.94M
Sb Management Ltd
7.8M sh · $75.7M
Two Sigma Advisers, LP
4.9M sh · $16.68M
Credit Suisse AG/
4.5M sh · $20.6M
Goldman Sachs Group Inc
4.3M sh · $14.86M
Ubs Group AG
4.2M sh · $14.69M
Arrowmark Colorado Holdings LLC
4.1M sh · $14.33M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
Hayden Michael R
Purchase · 53.6K shares
2026-08-24
★
DIRECTOR
Montalbano John S.
Purchase · 10.0K shares
2026-08-18
★
OFFICER: CHIEF FINANCIAL OFFICER
Booth Andrew
Purchase · 37.2K shares
2026-08-14
★
DIRECTOR
Hayden Michael R
Purchase · 46.4K shares
2026-08-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 1
MARKET PERFORM 1
5 GRADES IN THE LAST 12 MONTHS
Truist Securities BUY Cantor Fitzgerald OVERWEIGHT Stifel BUY Benchmark BUY Leerink Partners MARKET PERFORM

SECTORS PEERS

PEERPRICE
SYRE$90.36COMPARE
IMNM$27.57COMPARE
CLDX$39.12COMPARE
PHVS$35.32COMPARE
VERA$34.19COMPARE
BHVN$15.41COMPARE
NUVB$6.66COMPARE
XERS$8.48COMPARE